Pink Sheet Executive Editor Derrick Gingery and Senior Writer Sarah Karlin-Smith discuss the future of celebrity drug promotion after the US Food and Drug Administration flagged an AbbVie Inc. television ad featuring tennis star Serena Williams (:36), as well as the impact of the growing list of lawsuits questioning agency decisions now that the Chevron deference precedent has been overturned (13:32).
More On These Topics From The Pink Sheet
- Celebs Bring Extra Scrutiny To Advertisements, US FDA Tells AbbVie
- Lilly Challenges US FDA Classification Of Obesity Drug Retatrutide, Citing Chevron Overturn
- Life After Chevron: US Supreme Court Ruling Cited In FDA Exclusivity Decision Challenges
- US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide
This and other podcasts are available on the Pink Sheetpodcast page, as well as the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the topic areas, the coverage format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard. The survey should only take seven minutes to complete, and you get the chance to win an Amazon gift voucher just by taking part. The deadline for responses is 17 September. Take the survey. Thank you!
